R&D News | pharmaphorum

News

Moderna looks to its post-COVID growth prospects

With sales of its COVID-19 vaccines on the wane, Moderna has showcased the projects it will look to for the next phase of its development, headed by new vaccines for influ

News

Fresh from IPO, Acelyrin's lead drug fails clinical trial

Acelyrin has been flying high in the wake of an unusually large initial public offering (IPO) in May, but came down to earth with a bump today after a failed clinical tria

News

Novartis drops geographic atrophy gene therapy

Novartis has confirmed it will discontinue development of a gene therapy for sight-robbing disease geographic atrophy (GA) two years after acquiring its UK-based developer

News

WCLC: Chemo adds efficacy and side effects to AZ's Tagrisso

Giving AstraZeneca's EGFR tyrosine kinase inhibitor (TKI) inhibitor Tagrisso in combination with chemotherapy to patients with EGFR-mutated non-small cell lung cancer (NSC

News

First-in-class BMS drug raises lung fibrosis hopes

Bristol-Myers Squibb has proof-of-concept data for an experimental drug for fibrotic diseases that could open up a new avenue for treatment.

News

WCLC: Amgen eyes first-line use for KRAS drug Lumakras

Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is und

Moderna looks to its post-COVID growth prospects

Fresh from IPO, Acelyrin's lead drug fails clinical trial

Novartis drops geographic atrophy gene therapy

WCLC: Chemo adds efficacy and side effects to AZ's Tagrisso

First-in-class BMS drug raises lung fibrosis hopes

WCLC: Amgen eyes first-line use for KRAS drug Lumakras

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks